Company data sheet · Sinovac Biotech

Sinovac Biotech: growth far beyond its economy.

Industry
Pharmaceutical Preparations Manufacturing
Headquarters
China
Ticker
SVA (Nasdaq)
Sources
SEC filings (2000–2026), Stratrix's verified Decision Cases, market data and official economic statistics for China
Data as of
October 18, 2026
  1. From profit to three straight losses. Sinovac Biotech earned $0 billion in 2013–2013. Then it lost money every year from 2014 to 2016: $0 billion in all. 2017 was its first profit in four years: $0 billion.
  2. It outgrew its own economy many times over. Revenue rose from $0.1 billion in 2016 to $0.4 billion in 2025: 5.3 times as much. China's economy, counted the same way in money terms, grew about 83%. Whatever drove it, the economy around it does not account for growth of that size.
  3. Ahead of almost everyone like it. From 2016 to 2025, its revenue grew 436% in US dollars; the median among 181 large manufacturers grew 49%. It outgrew 96% of them.
  4. Still smaller than it was. Revenue reached $0.4 billion in 2025, 98% below its 2021 peak of $19.4 billion.

Financial results

Fiscal yearRevenueNet income
2016$0.1 billion−$0 billion
2017$0.2 billion$0 billion
2018$0.2 billion$0 billion
2019$0.2 billion$0 billion
2020$0.5 billion$0.1 billion
2021$19.4 billion$8.1 billion
2022$1.5 billion$0 billion
2023$0.5 billion−$0 billion
2024$0.4 billion$0 billion
2025$0.4 billion−$0.2 billion

As reported in its annual filings. Losses in red.

The full data sheet · Data Plan

Everything behind these findings, ready for your board deck.

  • Economic context: 3 measures for China, every year since 2016, from the official sources.
  • Peer comparison: against 264 companies of its size in its sector.
  • Financial results: ten years of revenue, operating and net income, and every annual report, linked.
  • Methods and sources, so each number can be checked and cited.

The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.